255 related articles for article (PubMed ID: 22635058)
1. Management of hyponatremia in heart failure: role of tolvaptan.
Albert NM; Chase S
J Cardiovasc Nurs; 2013; 28(2):176-86. PubMed ID: 22635058
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
3. Hyponatremia, heart failure, and the role of tolvaptan.
O'Connell JB; Alemayehu A
Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
[TBL] [Abstract][Full Text] [Related]
4. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
5. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Patel GP; Balk RA
Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
[TBL] [Abstract][Full Text] [Related]
6. Hyponatremia in hospitalized patients: the potential role of tolvaptan.
Deitelzweig SB; McCormick L
Hosp Pract (1995); 2011 Aug; 39(3):87-98. PubMed ID: 21881396
[TBL] [Abstract][Full Text] [Related]
7. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
9. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.
Friedman B; Cirulli J
J Crit Care; 2013 Apr; 28(2):219.e1-12. PubMed ID: 22884529
[TBL] [Abstract][Full Text] [Related]
10. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
Cavalcante JL; Khan S; Gheorghiade M
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms, risks, and new treatment options for hyponatremia.
Ghali JK
Cardiology; 2008; 111(3):147-57. PubMed ID: 18434717
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
Hori M
Future Cardiol; 2013 Mar; 9(2):163-76. PubMed ID: 23463968
[TBL] [Abstract][Full Text] [Related]
14. Role of vaptans in the management of hyponatremia.
Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A
Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
16. Conivaptan: promise of treatment in heart failure.
Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
[TBL] [Abstract][Full Text] [Related]
17. Current issues for nurse practitioners: Hyponatremia.
Haskal R
J Am Acad Nurse Pract; 2007 Nov; 19(11):563-79. PubMed ID: 17970857
[TBL] [Abstract][Full Text] [Related]
18. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists.
Elhassan EA; Schrier RW
Curr Opin Nephrol Hypertens; 2011 Mar; 20(2):161-8. PubMed ID: 21252664
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.
Josiassen RC; Curtis J; Filmyer DM; Audino B; Skuban N; Shaughnessy RA
Expert Opin Pharmacother; 2010 Mar; 11(4):637-48. PubMed ID: 20163274
[TBL] [Abstract][Full Text] [Related]
20. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
Ferguson-Myrthil N
Cardiol Rev; 2010; 18(6):313-21. PubMed ID: 20926941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
